
    
      The study is a phase II, randomised double-blind, placebo-controlled, cross-over trial. There
      are four periods: recruitment and randomisation; treatment period one (4 weeks); washout (1
      week); and finally treatment period two (4 weeks). Patients will be randomly assigned
      domperidone 20 mg tid in treatment period one followed by placebo tid in treatment period
      two, or placebo tid in treatment period one followed by domperidone 20 mg tid in treatment
      period two.
    
  